NVNO241220C2500
- 1.20
- 0.000.00%
enVVeno Medical Newsroom
EnVVeno Medical Highlights Successful 2024 VEITH Symposium With Launch of Recap Website
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain
EnVVeno Medical To Present Data From VenoValve Trial At 51st Annual VEITH Symposium; Data Includes Showing 85% Clinical Meaningful Benefit Responder Rate, 87% Median Ulcer Area Reduction
EnVVeno Medical to Present Definitive One Year Data From the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
EnVVeno Medical Submits PMA Application To FDA To Sell And Market VenoValve In The US
EnVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
10-Q: Q3 2024 Earnings Report
EnVVeno Medical Q3 EPS $(0.35) Misses $(0.33) Estimate
EnVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of This Year
EnVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating EnVVe(R)
Catalyst Watch: Tesla's Robotaxi Reveal, AI Events for Nvidia, AMD, and HP Enterprise
Correction: EnVVeno Medical Prices $15 Million Public Offering
Dow Surges Over 100 Points; Costco Earnings Top Views
Traders Digest Fed's Preferred Inflation Metric as US Equity Futures Waver Pre-Bell
Cassava Sciences, EnVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Top Premarket Decliners
EnVVeno Medical Stock Falls After It Prices $15M Securities Offering
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
12 Health Care Stocks Moving In Thursday's After-Market Session
EnVVeno Medical Corporation Announces Proposed Public Offering